An International Journal of Otorhinolaryngology Clinics

Register      Login

VOLUME 12 , ISSUE 1 ( January-April, 2020 ) > List of Articles


Study of Salivary Enzymes in Oral Lesions

Reshma P Chavan, Shivraj M Ingole, Shubhangi M Dalvi

Keywords : Malignant, Oral lesion, Salivary enzymes,Benign

Citation Information : Chavan RP, Ingole SM, Dalvi SM. Study of Salivary Enzymes in Oral Lesions. Int J Otorhinolaryngol Clin 2020; 12 (1):1-3.

DOI: 10.5005/jp-journals-10003-1348

License: CC BY-NC 4.0

Published Online: 03-03-2021

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Aim and objective: Saliva contains different enzymes, which reflect metabolic activities of the body. Certain enzymes, such as, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) enzymes are products of cell injury and cell death. Some benign oral conditions having malignant potential and therefore early changes in salivary enzyme level may be helpful for the early detection of malignancy. An attempt is made to compare salivary enzyme levels (AST and ALT) in benign oral lesions in tobacco addicts, malignant oral lesions in tobacco addicts, and healthy non-tobacco addict patients with age- and sex-matched control group. Material and methods: A retrospective study of 150 patients with benign and malignant oral lesions with tobacco addiction was done. Control group includes tobacco non-addicts. The oral lesion was noted. Biopsy of oral lesion was sent to histopathology for diagnosis. The saliva of all patients was collected for salivary enzymes (AST and ALT) examination. Levels of salivary enzymes (AST and ALT) in benign and malignant oral lesions of patients with tobacco addiction and tobacco non-addict control group without any oral lesions with age- and sex-matched study group were included in the study. The results were analyzed statistically by Student\'s t-test. Results: Salivary enzymes (AST and ALT) were not significantly increased in benign and malignant oral lesions in tobacco addict patients. Conclusion: Salivary enzymes were increased in all benign and malignant oral lesions in tobacco consumers. There was no significant increase in salivary enzymes in all benign and malignant oral lesions in tobacco consumers. Clinical significance: Research is going on salivary biomarkers, but these salivary biomarkers lack sensitivity and specificity and cannot be applied.

PDF Share
  1. Shah FD, Begum R, Vajaria BN, et al. A review on salivary genomics and proteomics biomarkers in oral cancer. Indian J Clin Biochem 2011;26:326–334. DOI: 10.1007/s12291-011-0149-8.
  2. Wong DT. Salivary diagnostics for oral cancer. J Calif Dent Assoc 2006;34:303–318.
  3. Dabra S, China K, Kaushik A. Salivary enzymes as diagnostic markers for detection of gingival/periodontal disease and their correlation with the severity of the disease. J Indian Soc Periodontol 2012;16:358–364. DOI: 10.4103/0972-124X.100911.
  4. Dewan A, Bhatia P. Evaluation of aspartate aminotransferase enzyme levels in saliva and gingival crevicular fluid with periodontal disease progression–A pilot study. J Int Oral Health 2011;3:19.
  5. Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase and serum alinine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther 2008;4:21–25. DOI: 10.4103/0973-1482.39601.
  6. Rai B, Kharb S, Anand SC. Salivary enzymes and thiocynate: salivary markers of periodontitis among smokers and non-smokers; a pilot study. Adv Med Dent Sci 2007;1:1–4.
  7. Rhodus NL, Ho V, Miller CS, et al. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42–45. DOI: 10.1016/j.cdp.2004.10.003.
  8. Rhodus NL, Cheng B, Myers S, et al. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 2005;44:77–82. DOI: 10.1002/mc.20113.
  9. Cheng Y, Wright J. Advances in diagnostic adjuncts for oral squamous cell carcinoma. Open Pathol J 2011;5:3–7. DOI: 10.2174/1874375701105010003.
  10. Chiappin S, Antonelli G, Gatti R, et al. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta 2007;383:30–40. DOI: 10.1016/j.cca.2007.04.011.
  11. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, et al. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009;10:E001–E008.
  12. Xiao H, Zhang L, Zhou H, et al. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 2012;11:M111.012112. DOI: 10.1074/mcp.M111.012112.
  13. Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009;29:71–85. DOI: 10.1016/j.cll.2009.01.004.
  14. Girja KP, Sundharam BS, Krishnan PA, et al. Biochemical changes of saliva in tobacco chewers tobacco smokers, alcohol consumers, leukoplakia and oral cancer patients. Indian J Dent Res 2002;13:102–107.
  15. Sato J, Goto J, Murata T, et al. Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:330–336. DOI: 10.1016/j.tripleo.2010.03.040.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.